Literature DB >> 25685647

Role of squamosal suture as a consistent landmark for middle fossa approach craniotomy: an anatomical study.

Kenan Alkhalili1, Mohammed Tantawy1, Mohab M Nageeb1, Mohamed A Ragaee1, Gasser H Alshyal1, Dunbar S Alcindor1, Douglas A Chen2, Khaled M Abdel Aziz1.   

Abstract

Objective To establish a consistent surface bony landmark for a middle fossa approach (MFA) lateral craniotomy represented by the squamosal suture (SS). Methods In 60 dried skulls, we assessed the relation between the SS and the external auditory canal (EAC). The lateral portion of the middle cranial fossa floor was also assessed for a possible relation with the anteroposterior diameter (APD) of the squama temporalis (ST). Clinically, we applied our findings on the SS in MFA for different lesions. Results A vertical line at the EAC divided the ST into the anterior part constituting 61% of the APD (i.e., two thirds) and the posterior part forming 39% (i.e., one third). The average ST height was 35.92 mm. The SS posterior limit at the supramastoid crest was located just anterior to the external projection of the petrous ridge in 35 skulls (58%) and exactly corresponded to it in 25 skulls (42%). The APD of the ST equals on average 97% of the APD of the lateral middle cranial fossa. Optimum exposure of the middle fossa was obtained without any further craniotomy extension. Conclusion The SS serves as a consistent natural surface bony landmark for MFA. Optimum craniotomy, two thirds anterior to the EAC and one third posterior, is obtained following SS as a landmark.

Keywords:  middle fossa approach; schwannoma; squamosal suture

Year:  2014        PMID: 25685647      PMCID: PMC4318743          DOI: 10.1055/s-0034-1390015

Source DB:  PubMed          Journal:  J Neurol Surg B Skull Base        ISSN: 2193-634X


  15 in total

1.  Supraarticular, supramastoid and suprameatal crests on the outer surface of the temporal bone and the relation between them.

Authors:  H Basri Turgut; A Anil; T Peker; C Pelin; I N Gülekon
Journal:  Surg Radiol Anat       Date:  2003-06-19       Impact factor: 1.246

2.  Surgical exposure of the internal auditory canal and its contents through the middle, cranial fossa.

Authors:  W F HOUSE
Journal:  Laryngoscope       Date:  1961-11       Impact factor: 3.325

Review 3.  Retrosigmoid approach: indications, techniques, and results.

Authors:  Mohamed Samy Elhammady; Fred F Telischi; Jacques J Morcos
Journal:  Otolaryngol Clin North Am       Date:  2012-04       Impact factor: 3.346

4.  Middle cranial fossa approach to acoustic tumor surgery.

Authors:  W F House; G Gardner; R L Hughes
Journal:  Arch Otolaryngol       Date:  1968-12

5.  Microanatomical study of the extradural middle fossa approach to the petroclival and posterior cavernous sinus region: description of the rhomboid construct.

Authors:  J D Day; T Fukushima; S L Giannotta
Journal:  Neurosurgery       Date:  1994-06       Impact factor: 4.654

6.  Durability of hearing preservation after microsurgical treatment of vestibular schwannoma using the middle cranial fossa approach.

Authors:  Anthony C Wang; Steven B Chinn; Khoi D Than; H Alexander Arts; Steven A Telian; Hussam K El-Kashlan; B Gregory Thompson
Journal:  J Neurosurg       Date:  2013-02-15       Impact factor: 5.115

Review 7.  Middle fossa approach: indications, technique, and results.

Authors:  Simon Angeli
Journal:  Otolaryngol Clin North Am       Date:  2012-04       Impact factor: 3.346

8.  Transpetrosal approach for aneurysms of the lower basilar artery.

Authors:  T Kawase; S Toya; R Shiobara; T Mine
Journal:  J Neurosurg       Date:  1985-12       Impact factor: 5.115

9.  Facial nerve function and hearing preservation acoustic tumor surgery: does the approach matter?

Authors:  Todd Hillman; Douglas A Chen; Moises A Arriaga; Matthew Quigley
Journal:  Otolaryngol Head Neck Surg       Date:  2010-01       Impact factor: 3.497

10.  The suprapetrosal craniotomy.

Authors:  Guilherme Carvalhal Ribas; Aldo Junqueira Júnior Rodrigues
Journal:  J Neurosurg       Date:  2007-03       Impact factor: 5.115

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.